News
Since January 2024, only 0.2% of people trying to quit smoking have used it (the same proportion that used it in 2018, when ...
6h
Barchart on MSNPfizer Stock Is a Value Play Ahead of Earnings - Investors Can Short PFE Puts for IncomePfizer, Inc. (PFE) stock still looks cheap ahead of its upcoming Aug. 5 Q2 earnings release. Moreover, investors can make extra income by selling out-of-the-money (OTM) put options. This article ...
Income-focused investors actively pursuing high yielders should understand what they stand to sacrifice by reaching for a ...
According to the European Union, in 2024, EU exports of medicinal and pharmaceutical products increased by 13.5% compared ...
In 2025, the Depo-Provera lawsuit is real and legitimate. Millions have used it — but the risk of brain tumors was only ...
9h
Zacks Investment Research on MSNPfizer (PFE) Expected to Beat Earnings Estimates: Should You Buy?Wall Street expects a year-over-year decline in earnings on higher revenues when Pfizer (PFE) reports results for the quarter ...
Explore more
Urologic cancers, which include prostate, bladder, and kidney malignancies, pose significant global health challenges due to ...
I can’t ask you to do that because we are still on the verge of finding out what the Seagen acquisition does. Let’s give Dr.
Do you know how hard it is to find a stock as bad as Pfizer Inc (NYSE:PFE) like in the last couple of years? I managed the ...
Antibody-drug conjugates are a growing class of biopharmaceuticals that combine the precision of monoclonal antibodies with ...
Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...
Currently, a multidistrict litigation against Pfizer (NYSE: PFE) is underway on behalf of women who claim to have developed meningiomas after receiving four or more consecutive injections of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results